IP Library Granted Patent US 10,828,249
Granted Patent B2
US 10,828,249 · App. 15/492,528 · Granted Nov 10, 2020

Deep topical systemic nitric oxide therapy apparatus and method

Inventors: Christian S. Minton (Provo, UT); Stephen D. Minton (Provo, UT); J. W. Randolph Miller (Orem, UT)
Assignee: SYK TECHNOLOGIES, LLC
A61K9/0014A61K33/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,828,249
App. No.
15/492,528
Granted
Nov 10, 2020
Kind
B2
Abstract

A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance.

Claims (39)

1. A method for increasing vasodilation comprising:

providing a mammal with an epidermal surface and a bloodstream having an initial systemic vasodilation of the bloodstream;

providing a first medium comprising a nitrite compound;

providing a second medium comprising at least two reducing agents;

creating a mixture of the first medium and the second medium thereby initiating production of nitric oxide;

applying the mixture onto a first location of the epidermal surface of the mammal;

absorbing at least 500 ppm of nitric oxide transdermally within 10 minutes after the applying; and

increasing the systemic vasodilation of the bloodstream at a second, untreated location of the mammal as compared to the initial systemic vasodilation.

2. The method of claim 1 , wherein the epidermal surface is healthy skin.

3. The method of claim 1 , wherein the mixture includes a salt buffer concentration for prolonging the production of nitric oxide, wherein the salt used in the salt buffer includes at least one salt selected from a group consisting of sodium chloride and calcium chloride.

4. The method of claim 1 , further comprising treating the mammal for peripheral artery disease.

5. The method of claim 1 , further comprising covering the epidermal surface with a barrier after applying the mixture.

6. The method of claim 1 , wherein the first medium includes at least one nitrite selected from a group consisting of sodium nitrite and potassium nitrite.

7. The method of claim 1 , wherein the second medium includes at least two reducing agents selected from a group consisting of citric acid, ascorbic acid, phytic acid, acetic acid, formic acid, and lactic acid.

8. The method of claim 1 , wherein the first and second mediums further include a thickening agent derived from cellulose in an amount between 0.80% and 0.120%.

9. The method of claim 1 , wherein the first medium further comprises sodium bicarbonate.

10. A method for treating systemic hemodynamic disorders comprising:

providing a mammal with an epidermal surface and a bloodstream having a systemic hemodynamic disorder;

providing a first medium comprising a nitrite compound and sodium bicarbonate;

providing a second medium comprising a reducing agent;

creating a mixture of the first medium and the second medium thereby initiating production of nitric oxide;

applying the mixture onto a first location of the epidermal surface of the mammal; and

increasing systemic vasodilation of the bloodstream at a second, unapplied location of the mammal to treat the systemic hemodynamic disorder.

11. The method of claim 10 , wherein the systemic hemodynamic disorder is peripheral artery disease.

12. The method of claim 10 , wherein the second medium includes at least two reducing agents selected from a group consisting of citric acid, ascorbic acid, phytic acid, acetic acid, formic acid, and lactic acid.

13. The method of claim 10 , wherein the mixture includes a salt buffer concentration for prolonging the production of nitric oxide, wherein the salt used in the salt buffer includes at least one salt selected from a group consisting of sodium chloride and calcium chloride.

14. The method of claim 10 , further comprising repeating the previous steps within three days.

15. A method for increasing vasodilation comprising:

providing a mammal with an epidermal surface and a bloodstream having an initial systemic vasodilation of the bloodstream;

providing a first medium comprising a nitrite compound;

providing a second medium comprising at least two reducing agents;

creating a mixture of the first medium and the second medium thereby initiating production of nitric oxide, wherein the mixture also includes a salt buffer for prolonging the production of nitric oxide, wherein the salt used in the salt buffer includes at least one salt selected from a group consisting of sodium chloride and calcium chloride;

treating, by applying the mixture onto a first location of the epidermal surface of the mammal;

absorbing an effective amount of nitric oxide transdermally; and

increasing the systemic vasodilation of the bloodstream at a second, untreated location of the mammal as compared to the initial systemic vasodilation.

16. The method of claim 15 , wherein the epidermal surface is healthy skin.

17. The method of claim 15 , further comprising covering the epidermal surface with a barrier after applying the mixture.

18. The method of claim 15 , wherein the first medium further comprises sodium bicarbonate.

19. The method of claim 15 , wherein the first and second mediums further include a thickening agent derived from cellulose in an amount between 0.80% and 0.120%.

Assignments (5)
SECURITY INTEREST Recorded Apr 24, 2024
From: NO2020, LLC
To: KNOBBE, MARTENS, OLSON & BEAR, LLP
Reel/Frame 067217/0866 →
SECURITY INTEREST Recorded Apr 24, 2024
From: SYK TECHNOLOGIES LLC
To: KNOBBE, MARTENS, OLSON & BEAR, LLP
Reel/Frame 067217/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2022
From: GENOSYS
To: PATE BAIRD, PLLC
Reel/Frame 059036/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2022
From: PATE BAIRD, PLLC
To: SY KIMBALL
Reel/Frame 059037/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2022
From: KIMBALL, SY
To: SYK TECHNOLOGIES, LLC
Reel/Frame 059037/0516 →
Continuity (5)
Division 14274419 · May 9, 2014
Provisional Application 61821443 · May 9, 2013
Provisional Application 61888415 · Oct 8, 2013
Provisional Application 61990591 · May 8, 2014
Related Publication 20170296463A1 · Oct 19, 2017
Cited By (1)
US 12,459,820